RP3

RP3 is a genetically modified oncolytic immunotherapy based on herpes simplex virus 1 (HSV-1). It is engineered to express several immune-stimulatory molecules, including a fusogenic glycoprotein (GALV-GP), an anti–cytotoxic T lymphocyte antigen 4 (CTLA-4) antibody-like molecule, CD40 ligand, and 4-1BB ligand. These modifications are designed to enhance the virus’s ability to kill tumor cells directly (oncolysis), promote cell-to-cell spread, induce immunogenic cell death, and activate systemic antitumor immune responses. RP3 has demonstrated antitumor activity in preclinical models both as monotherapy and in combination with PD-1 blockade. It is being developed for use in solid tumors—including hepatocellular carcinoma and colorectal cancer—both alone and in combination with other immunotherapies such as nivolumab or atezolizumab plus bevacizumab[2][3][7].